Xenetic Biosciences, Inc. 8-K

0001683168-24-004415.txt : 20240621 0001683168-24-004415.hdr.sgml : 20240621 20240621163043 ACCESSION NUMBER: 0001683168-24-004415 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240618 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240621 DATE AS OF CHANGE: 20240621 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenetic Biosciences, Inc. CENTRAL INDEX KEY: 0001534525 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452952962 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37937 FILM NUMBER: 241060925 BUSINESS ADDRESS: STREET 1: 945 CONCORD ST. CITY: FRAMINGHAM STATE: MA ZIP: 01701 BUSINESS PHONE: 781-778-7720 MAIL ADDRESS: STREET 1: 945 CONCORD ST. CITY: FRAMINGHAM STATE: MA ZIP: 01701 FORMER COMPANY: FORMER CONFORMED NAME: General Sales & Leasing, Inc. DATE OF NAME CHANGE: 20130227 FORMER COMPANY: FORMER CONFORMED NAME: GENERAL AIRCRAFT INC. DATE OF NAME CHANGE: 20111108 8-K 1 xenetic_8k.htm 8-K Xenetic Biosciences, Inc. 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 8-K

________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2024

________________________

Xenetic Biosciences, Inc.

(Exact name of registrant as specified in charter)

Nevada		001-37937		45-2952962
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

945 Concord Street
Framingham, Massachusetts	01701
(Address of principal executive offices)	(Zip Code)

(781) 778-7720

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		XBIO		The Nasdaq Stock Market
Purchase Warrants		XBIOW		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously disclosed, on May 16, 2024, the Board of Directors of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer. In connection with the foregoing, on June 18, 2024, the Company and Mr. Parslow entered into an amendment (the “Amendment”) to that certain employment agreement, dated March 23, 2017, by and between the Company and Mr. Parslow, to provide for, effective as of May 16, 2024: (i) certain changes to Mr. Parslow’s title and responsibilities; (ii) an increase in Mr. Parslow’s base salary to $400,000; (iii) a $100,000 cash retention bonus if Mr. Parslow remains employed with the Company for a ten month period; and (iv) a stock option grant to Mr. Parslow to purchase 20,000 shares of common stock of the Company with an exercise price equal to the fair market value of the Company’s common stock on the effective date of the Amendment. Such option grant shall be issued pursuant to the terms and conditions of the Company’s Amended and Restated Equity Incentive Plan, and shall vest one-fourth on the grant date and one-fourth upon the first, second and third anniversaries of the grant date, provided Mr. Parslow remains employed with the Company on the applicable vesting date. All other terms of Mr. Parslow’s employment agreement as previously disclosed remain in full force and effect.

On June 19, 2024, the Company entered into a confidential separation agreement and general release with each of and Jeffrey F. Eisenberg, the Company’s former Chief Executive Officer (the “Eisenberg Separation Agreement”), and Curtis Lockshin, the Company’s former Chief Scientific Officer (the “Lockshin Separation Agreement” and together, the “Separation Agreements”) pursuant to which Messrs. Eisenberg and Lockshin will each be eligible for certain severance payments and benefits consistent with the terms of his existing employment agreement as described under “Employment Agreements with our Named Executive Officers” in the Amendment No. 1 to Annual Report on Form 10-K/A filed by the Company with the Securities and Exchange Commission on April 26, 2024. In addition, the Eisenberg Separation Agreement provides for accelerated vesting of all of the unvested stock options held by Mr. Eisenberg as of May 16, 2024.

The foregoing descriptions of the Amendment and the Separation Agreements are qualified in their entirety by reference to the full text of the Amendment and Separation Agreements, copies of which will be filed as exhibits to the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2024, and are incorporated herein by reference.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	XENETIC BIOSCIENCES, INC.

	By: /s/ James Parslow
Date: June 21, 2024	Name: James Parslow
	Title: Interim Chief Executive Officer and Chief Financial Officer

3

EX-101.SCH 2 xbio-20240618.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 xbio-20240618_def.xml XBRL DEFINITION FILE EX-101.LAB 4 xbio-20240618_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock 0. 001 Par Value Per Share [Member] Purchase Warrants [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 xbio-20240618_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 18, 2024
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 18, 2024
Entity File Number	001-37937
Entity Registrant Name	Xenetic Biosciences, Inc.
Entity Central Index Key	0001534525
Entity Tax Identification Number	45-2952962
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	945 Concord Street
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01701
City Area Code	(781)
Local Phone Number	778-7720
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock 0. 001 Par Value Per Share [Member]
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	XBIO
Security Exchange Name	NASDAQ
Purchase Warrants [Member]
Title of 12(b) Security	Purchase Warrants
Trading Symbol	XBIOW
Security Exchange Name	NASDAQ

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 3 22 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://xeneticbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports xbio-20240618.xsd xbio-20240618_def.xml xbio-20240618_lab.xml xbio-20240618_pre.xml xenetic_8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xenetic_8k.htm": { "nsprefix": "XBIO", "nsuri": "http://xeneticbio.com/20240618", "dts": { "schema": { "local": [ "xbio-20240618.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "xbio-20240618_def.xml" ] }, "labelLink": { "local": [ "xbio-20240618_lab.xml" ] }, "presentationLink": { "local": [ "xbio-20240618_pre.xml" ] }, "inline": { "local": [ "xenetic_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 25 }, "report": { "R1": { "role": "http://xeneticbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "xenetic_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "xenetic_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://xeneticbio.com/role/Cover" ], "auth_ref": [] }, "XBIO_CommonStock0.001ParValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240618", "localname": "CommonStock0.001ParValuePerShareMember", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock 0. 001 Par Value Per Share [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "XBIO_PurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240618", "localname": "PurchaseWarrantsMember", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Purchase Warrants [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001683168-24-004415-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-004415-xbrl.zip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end XML 17 xenetic_8k_htm.xml IDEA: XBRL DOCUMENT 0001534525 2024-06-18 2024-06-18 0001534525 XBIO:CommonStock0.001ParValuePerShareMember 2024-06-18 2024-06-18 0001534525 XBIO:PurchaseWarrantsMember 2024-06-18 2024-06-18 iso4217:USD shares iso4217:USD shares false 0001534525 8-K 2024-06-18 Xenetic Biosciences, Inc. NV 001-37937 45-2952962 945 Concord Street Framingham MA 01701 (781) 778-7720 false false false false Common Stock, $0.001 par value per share XBIO NASDAQ Purchase Warrants XBIOW NASDAQ false